Your browser doesn't support javascript.
loading
TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.
Zhou, Yanhong; Lin, Ruitao; Lee, J Jack; Li, Daniel; Wang, Li; Li, Ruobing; Yuan, Ying.
Affiliation
  • Zhou Y; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Lin R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Li D; Juno Therapeutics, Bristol-Myers Squibb Company, Seattle, Washington, USA.
  • Wang L; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois, USA.
  • Li R; The Center for Drug Evaluation, The National Medical Products Administration, Beijing, China.
  • Yuan Y; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Stat Med ; 41(11): 1918-1931, 2022 05 20.
Article in En | MEDLINE | ID: mdl-35098585
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Clinical Trials, Phase II as Topic / Clinical Trials, Phase I as Topic Type of study: Prognostic_studies Limits: Humans Language: En Journal: Stat Med Year: 2022 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Clinical Trials, Phase II as Topic / Clinical Trials, Phase I as Topic Type of study: Prognostic_studies Limits: Humans Language: En Journal: Stat Med Year: 2022 Type: Article Affiliation country: United States